MedTrace Logo

Acute Effect of Exenatide on Brain Glucose Metabolism

NCT01588418 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-11-24

Study results available
· View outcomes & findings →

Summary

This research study will examine brain glucose metabolism after an overnight fast to determine the effect of exenatide on brain glucose metabolism and lipid metabolism.

Conditions

  • Impaired Glucose Tolerance (IGT)
  • Diabetes

Interventions

DRUG

Exenatide

Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study

DRUG

Placebo

Placebo was administered in random order 30 min before OGTT-PET study in the same subject

Sponsors & Collaborators

  • Amylin Pharmaceuticals, LLC.

    collaborator INDUSTRY

  • The University of Texas Health Science Center at San Antonio

    lead OTHER

Principal Investigators

  • Amalia Gastaldelli, PhD · UTHSCSA, San Antonio, TX

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-07-31
Primary Completion
2015-07-31
Completion
2015-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01588418 on ClinicalTrials.gov